Q3 Earnings Forecast for McKesson Issued By Leerink Partnrs

McKesson Corporation (NYSE:MCK) – Leerink Partnrs boosted their Q3 2026 earnings per share estimates for McKesson in a research note issued on Tuesday, September 23rd. Leerink Partnrs analyst M. Cherny now expects that the company will earn $10.11 per share for the quarter, up from their previous estimate of $9.77. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson’s Q4 2026 earnings at $11.36 EPS, FY2026 earnings at $38.35 EPS, FY2027 earnings at $43.82 EPS and FY2028 earnings at $49.69 EPS.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, August 6th. The company reported $8.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.33 by ($0.07). The firm had revenue of $97.83 billion during the quarter, compared to analysts’ expectations of $95.93 billion. McKesson had a net margin of 0.84% and a negative return on equity of 196.66%. The firm’s revenue for the quarter was up 23.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $7.88 EPS.

MCK has been the subject of several other research reports. Mizuho raised their price objective on shares of McKesson from $750.00 to $770.00 and gave the company a “neutral” rating in a research note on Wednesday. UBS Group raised their price target on shares of McKesson from $820.00 to $860.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners upped their price objective on McKesson from $785.00 to $850.00 and gave the stock an “outperform” rating in a research report on Wednesday. Evercore ISI lifted their target price on McKesson from $800.00 to $825.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Wells Fargo & Company boosted their target price on McKesson from $772.00 to $816.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $826.91.

McKesson Price Performance

Shares of McKesson stock opened at $737.65 on Thursday. The stock has a market capitalization of $91.75 billion, a price-to-earnings ratio of 29.41, a price-to-earnings-growth ratio of 1.47 and a beta of 0.51. The business has a 50-day moving average of $696.77 and a 200 day moving average of $698.45. McKesson has a 12 month low of $472.50 and a 12 month high of $770.00.

Institutional Trading of McKesson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Solstein Capital LLC boosted its holdings in shares of McKesson by 171.4% in the 2nd quarter. Solstein Capital LLC now owns 38 shares of the company’s stock valued at $28,000 after buying an additional 24 shares in the last quarter. State of Wyoming purchased a new stake in McKesson in the second quarter valued at $29,000. GFG Capital LLC purchased a new stake in McKesson in the second quarter valued at $30,000. CBIZ Investment Advisory Services LLC grew its holdings in shares of McKesson by 1,366.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 44 shares of the company’s stock worth $30,000 after purchasing an additional 41 shares during the last quarter. Finally, Bank of Jackson Hole Trust increased its position in shares of McKesson by 64.3% during the first quarter. Bank of Jackson Hole Trust now owns 46 shares of the company’s stock worth $29,000 after purchasing an additional 18 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Activity

In other news, CEO Brian S. Tyler sold 19,371 shares of the company’s stock in a transaction dated Friday, July 11th. The stock was sold at an average price of $708.09, for a total transaction of $13,716,411.39. Following the completion of the transaction, the chief executive officer directly owned 27,872 shares of the company’s stock, valued at approximately $19,735,884.48. This represents a 41.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $663.67, for a total value of $218,347.43. Following the completion of the transaction, the chief accounting officer owned 657 shares in the company, valued at approximately $436,031.19. The trade was a 33.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,560 shares of company stock valued at $30,438,602. Insiders own 0.08% of the company’s stock.

McKesson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Tuesday, September 2nd will be issued a dividend of $0.82 per share. This is a positive change from McKesson’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Tuesday, September 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 13.08%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.